Novavax Ceo
-
{
- All
- News
- Videos
-
Novavax Covid Vaccine Gets First Authorization, "More Expected" Says CEO
Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within "weeks," its CEO said after the shot received its first emergency use authorization (EUA) from Indonesia.
-
Novavax May Get Approval In 2 Months, Likely To Cost More Than Covishield
The Covovax shot developed by American vaccine-maker Novavax would cost a "low single dollar" price per dose but is likely to be costlier than Covishield, company's CEO Stanley Erck said in an exclusive interview.
-
"Hope To Launch Covovax By June 2021": Serum Institute's Adar Poonawalla
Serum Institute of India, the world's biggest vaccine maker, is hopeful of launching Covovax - developed in partnership with American vaccine developer Novavax - by June, its CEO Adar Poonawalla said today. The US-based pharma firm's Covid jab was found to be 89.3 per cent effective in a UK trial.
-
Serum Institute Seeks India Trial Of A Second Covid Vaccine
The Serum Institute of India, the world's biggest vaccine makers, has sought the drug regulator's permission to conduct a small domestic trial of the Novavax Inc COVID-19 vaccine that was found to be 89.3% effective in a UK trial, its CEO told Reuters on Friday.
-
Serum Institute To Stockpile Novavax Vaccine From April: Adar Poonawalla
The Serum Institute of India, the world's biggest vaccine maker, will start stockpiling millions of doses of the Novavax coronavirus vaccine candidate starting around April, CEO Adar Poonawalla told the Reuters Next conference on Thursday.
-
Novavax CEO Expects Filing For Covid Vaccine Approval In December: Report
Novavax Inc expects filing for approval of its COVID-19 vaccine candidate in the United States in December, Chief Executive Stanley Erck said in an interview for Czech daily Hospodarske Noviny, released on Thursday.
-
Novavax Covid Vaccine Gets First Authorization, "More Expected" Says CEO
Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within "weeks," its CEO said after the shot received its first emergency use authorization (EUA) from Indonesia.
-
Novavax May Get Approval In 2 Months, Likely To Cost More Than Covishield
The Covovax shot developed by American vaccine-maker Novavax would cost a "low single dollar" price per dose but is likely to be costlier than Covishield, company's CEO Stanley Erck said in an exclusive interview.
-
"Hope To Launch Covovax By June 2021": Serum Institute's Adar Poonawalla
Serum Institute of India, the world's biggest vaccine maker, is hopeful of launching Covovax - developed in partnership with American vaccine developer Novavax - by June, its CEO Adar Poonawalla said today. The US-based pharma firm's Covid jab was found to be 89.3 per cent effective in a UK trial.
-
Serum Institute Seeks India Trial Of A Second Covid Vaccine
The Serum Institute of India, the world's biggest vaccine makers, has sought the drug regulator's permission to conduct a small domestic trial of the Novavax Inc COVID-19 vaccine that was found to be 89.3% effective in a UK trial, its CEO told Reuters on Friday.
-
Serum Institute To Stockpile Novavax Vaccine From April: Adar Poonawalla
The Serum Institute of India, the world's biggest vaccine maker, will start stockpiling millions of doses of the Novavax coronavirus vaccine candidate starting around April, CEO Adar Poonawalla told the Reuters Next conference on Thursday.
-
Novavax CEO Expects Filing For Covid Vaccine Approval In December: Report
Novavax Inc expects filing for approval of its COVID-19 vaccine candidate in the United States in December, Chief Executive Stanley Erck said in an interview for Czech daily Hospodarske Noviny, released on Thursday.
